Oxybutynin

• CAT Number: A000922
• CAS Number: 5633-20-5
• Molecular Formula: C22H31NO3
• Molecular Weight: 357.49
• Purity: ≥95%
• Synonyms: 5633-20-5; Ditropan; Oxytrol; Oxibutyninum; Oxybutynine
• Target: Neuronal Signaling
• Solubility: Soluble in DMSO > 10 mM
• Storage: -20°C
• InChI: 1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3
• InChIKey: XIQVNETUBQGFHX-UHFFFAOYSA-N
• SMILES: CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O

Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination (urge incontinence), by decreasing muscle spasms of the bladder. It is also given to help with symptoms associated with kidney stones.

Reference

1: Maldonado-Alcaraz E, Moreno-Palacios J, López-Sámano VA, Landa-Salas C,
Torres-Mercado LO, GarcíaCruz C. [Tamsulosin, oxybutynin or their combination in
the treatment of ureteral stent-related symptoms]. Rev Med Inst Mex Seguro Soc.
2017 Sep-Oct;55(5):568-574. Spanish. PubMed PMID: 29193937.

2: Vozmediano-Chicharro R, Blasco Hernández P, Madurga-Patuel B. [Tolerability,
persistence and satisfaction. Retrospective cohort study in patients with
overactive bladder syndrome treated with transdermal Oxybutynin under Standard
ClinicAl pRactice. OSCAR Study.]. Arch Esp Urol. 2017 Jul;70(6):561-569. Spanish.
PubMed PMID: 28678009.

3: Artzi O, Loizides C, Zur E, Sprecher E. Topical Oxybutynin 10% Gel for the
Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind
Placebo-controlled Split Area Study. Acta Derm Venereol. 2017 Oct
2;97(9):1120-1124. doi: 10.2340/00015555-2731. PubMed PMID: 28654131.

4: Aprile S, Canavesi R, Matucci R, Bellucci C, Del Grosso E, Grosa G. New
insights in the metabolism of oxybutynin: evidence of N-oxidation of
propargylamine moiety and rearrangement to enaminoketone. Xenobiotica. 2017 Jul
6:1-10. doi: 10.1080/00498254.2017.1342288. [Epub ahead of print] PubMed PMID:
28608746.

5: Delort S, Marchi E, Corrêa MA. Oxybutynin as an alternative treatment for
hyperhidrosis. An Bras Dermatol. 2017 Mar-Apr;92(2):217-220. doi:
10.1590/abd1806-4841.201755126. Review. PubMed PMID: 28538882; PubMed Central
PMCID: PMC5429108.

6: Tekin B, Karadag AS, Koska MC. Oral oxybutynin for multiple eccrine
hidrocystomas. J Am Acad Dermatol. 2017 Jun;76(6):e203-e204. doi:
10.1016/j.jaad.2017.01.024. PubMed PMID: 28522061.

7: Lembrança L, Wolosker N, de Campos JRM, Kauffman P, Teivelis MP, Puech-Leão P.
Videothoracoscopic Sympathectomy Results after Oxybutynin Chloride Treatment
Failure. Ann Vasc Surg. 2017 Aug;43:283-287. doi: 10.1016/j.avsg.2017.01.018.
Epub 2017 May 3. PubMed PMID: 28478174.

8: Toledo-Pastrana T, Márquez-Enríquez J, Millán-Cayetano JF. Oral Oxybutynin for
Local and Multifocal Hyperhidrosis: A Multicenter Study. Actas Dermosifiliogr.
2017 Jul – Aug;108(6):597-599. doi: 10.1016/j.ad.2016.11.013. Epub 2017 Apr 5.
English, Spanish. PubMed PMID: 28388990.

9: Borch L, Hagstroem S, Kamperis K, Siggaard CV, Rittig S. Transcutaneous
Electrical Nerve Stimulation Combined with Oxybutynin is Superior to Monotherapy
in Children with Urge Incontinence: A Randomized, Placebo Controlled Study. J
Urol. 2017 Mar 19. pii: S0022-5347(17)40343-0. doi: 10.1016/j.juro.2017.03.117.
[Epub ahead of print] PubMed PMID: 28327453.

10: Pariser DM, Krishnaraja J, Tremblay TM, Rubison RM, Love TW, McGraw BF.
Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and
Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in
Subjects With Primary Focal Hyperhidrosis. J Drugs Dermatol. 2017 Feb
1;16(2):127-132. PubMed PMID: 28300854.